GlassScriptPhysician profile
Mona C Zaher
NPI 1659436319
$688.79
in general payments reported to CMS, 2019-2025
13 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2023: $29.96 · 2024: $129 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $166.75 | 2025 | |
| Dexcom, INC. | $146.09 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $71.22 | 2019-2023 | Mounjaro |
| Blueprint Medicines Corporation | $60.09 | 2025 | Ayvakit |
| Ucb, INC. | $43.81 | 2019 | |
| Celgene Corporation | $42.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $40.90 | 2019 | |
| Senseonics, Incorporated | $34.00 | 2019 | |
| Mannkind Corporation | $24.24 | 2019 | |
| Beta Bionics, INC. | $23.13 | 2024 | Ilet Bionic Pancreas |
| Shire North American Group INC | $12.60 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $12.48 | 2019 | |
| Merck Sharp & Dohme LLC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Zaher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.